|
|
|
|
||
Will Be Interesting to Hear Celgene's Guidance in Jan. 2013 on AbraxaneWith Abraxane's superior results in pancreatic cancer and being able to be prescribed off label, it will be interesting to hear Celgene's guidance for off label sales at Jan's JP Morgan Biotech Conference in Jan 2013.
|
return to message board, top of board |